CardioDx, Inc. Multi-Center Trial Validates Blood-Based Gene Expression Test to Assess the Presence of Obstructive Coronary Artery Disease

PALO ALTO, Calif.--(BUSINESS WIRE)--CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, today announced publication of results from the Personalized Risk Evaluation and Diagnosis In the Coronary Tree (PREDICT) trial in the Annals of Internal Medicine, the journal of the American College of Physicians.